<DOC>
	<DOCNO>NCT00524563</DOCNO>
	<brief_summary>The primary objective ass independent predictor in-hospital mortality ( 28 day ) patient Acinetobacter bloodstream infection . Secondary Objectives include follow : To determine impact inactive empiric antimicrobial therapy , define receipt empiric antimicrobial therapy vitro activity offend isolate least 24hrs , outcome ( end point define ) patient Acinetobacter bloodstream infection . To determine impact carbapenem resistance pan-drug resistance ( define resistance antimicrobial except colistin and/or tigecycline agent test ) outcome patient Acinetobacter bloodstream infection . To assess efficacy vary definitive therapy outcome patient Acinetobacter bloodstream infection . To characterize molecular epidemiology Acinetobacter global level , determine pulsed-field gel electrophoresis ( PFGE ) technique , ass whether patient outcome clonally related characterize mechanism resistance Acinetobacter global scale .</brief_summary>
	<brief_title>Clinical Outcomes Global Epidemiology -Data Coordinating Center</brief_title>
	<detailed_description>Medical record review information collect chart assess independent predictor in-hospital mortality ( 28 day ) patient Acinetobacter bloodstream infection . 24 site participate information load password protect database .</detailed_description>
	<mesh_term>Acinetobacter Infections</mesh_term>
	<criteria>Acinetobacter bloodstream infection Does meet entry criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Acinetobacter</keyword>
	<keyword>bloodstream infection</keyword>
	<keyword>Isolate</keyword>
</DOC>